caa a22 4500 397590563 CHVBK 20180308164937.0 cr unu---uuuuu 161202e199607 xx s 000 0 eng 10.1093/jac/38.1.117 doi (NATIONALLICENCE)oxford-10.1093/jac/38.1.117 Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients [Elektronische Daten] [V. Joly, C. Geoffary, J. Reynes, C. Goujard, D. Méchali, C. Maslo, F. Raffi, P. Yeni] We determined the safety and efficacy of deoxycholate-amphotericin B (d-AmB) mixed with Intralipid (IL) as the initial treatment of AIDS-associated cryptococcal meningitis in a phase II, multicentre, non-comparative open study, assessing two dosages of ILd-AmB: 1 mg/kg (group A, n = 9) and 1.5 mg/kg (group B, n = 6). Patients were treated daily for 2 weeks, then three times weekly for 4 weeks. The ILd-AmB dosage was decreased due to toxicity in three patients in each group. Serum creatinine increased significantly on day 14 in group A and on day 7 in group B. Nephrotoxicity, (serum creatinine level >165 μmol/L) was noted in two and five patients in groups A and B, respectively. Nine adverse haematological events were noted (seven cases of anaemia requiring transfusion, and two cases of neutropenia < 750/mm). Two patients had an increase in serum alkaline phosphatase. In each cohort, 15% of the infusions were associated with fever and/or chills. Successful outcome was obtained in half of the patients. We conclude that, in AIDS patients with cryptococcosis, tolerance to ILd-AmB was acceptable when the daily dosage did not exceed 1 mg/kg, but the higher 1.5 mg/kg daily dosage was associated with an unacceptable rate of nephrotoxicity. Neither of these relatively high daily dosages of ILd-AmB achieved an improved rate of successful outcomes compared with lower daily dosages of conventional d-AmB in glucose. © 1996 by the British Society for Antimicrobial Chemotherapy Original articles nationallicence Joly V. Hôpital Bichat-Claude Bernard Paris aut Geoffary C. Hôpital Bichat-Claude Bernard Paris aut Reynes J. Hôpital Gui de Chauliac Montpellier aut Goujard C. Hôpital Antoine Béclére Clamart aut Méchali D. Hôpital La Fontaine Saint Denis aut Maslo C. Hôpital Rothschild Paris aut Raffi F. Hôtel-Dieu Nantes, France aut Yeni P. Hôpital Bichat-Claude Bernard Paris aut Journal of Antimicrobial Chemotherapy Oxford University Press 38/1(1996-07), 117-126 0305-7453 38:1<117 1996 38 jac https://doi.org/10.1093/jac/38.1.117 text/html Onlinezugriff via DOI 1 other jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/38.1.117 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Joly V. Hôpital Bichat-Claude Bernard Paris aut NATIONALLICENCE 700 1- Geoffary C. Hôpital Bichat-Claude Bernard Paris aut NATIONALLICENCE 700 1- Reynes J. Hôpital Gui de Chauliac Montpellier aut NATIONALLICENCE 700 1- Goujard C. Hôpital Antoine Béclére Clamart aut NATIONALLICENCE 700 1- Méchali D. Hôpital La Fontaine Saint Denis aut NATIONALLICENCE 700 1- Maslo C. Hôpital Rothschild Paris aut NATIONALLICENCE 700 1- Raffi F. Hôtel-Dieu Nantes, France aut NATIONALLICENCE 700 1- Yeni P. Hôpital Bichat-Claude Bernard Paris aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 38/1(1996-07), 117-126 0305-7453 38:1<117 1996 38 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford